Precision BioSciences Bolsters HBV Program IP with Key Patent Allowances
Event summary
- Precision BioSciences received two Notices of Allowance from the USPTO for patent applications related to its PBGENE-HBV program.
- Application No. 19/347,136 covers the ARCUS nuclease used in PBGENE-HBV, providing composition-of-matter protection.
- Application No. 19/273,982 covers a novel polypeptide linker, potentially applicable to future ARCUS nucleases.
- The granted patents are expected to expire in November 2044.
- PBGENE-HBV is currently in a Phase 1/2 clinical trial targeting Hepatitis B cccDNA elimination.
The big picture
The patent allowances strengthen Precision BioSciences’ intellectual property position in a competitive gene editing landscape, particularly as in vivo gene editing for chronic viral infections gains traction. While the PBGENE-HBV program represents a significant opportunity, the company's success hinges on demonstrating clinical efficacy and defending its IP. The broader gene editing market is attracting substantial investment, and robust IP protection is essential for securing long-term value.
What we're watching
- Clinical Efficacy
- The clinical trial data for PBGENE-HBV will be critical in determining the therapeutic potential of the ARCUS platform for in vivo gene editing and the value of the newly protected IP.
- Patent Defense
- The strength and enforceability of these patents against potential challenges from competitors will influence Precision BioSciences’ long-term market position.
- Platform Expansion
- How quickly Precision BioSciences can leverage the novel linker technology to develop and patent new ARCUS nucleases for other therapeutic targets will indicate the platform’s versatility.
Related topics